The Data Relationship

SunwArt - Stock.adobe.com

As the world becomes increasingly data-driven and the need for standardization and transparency between the various sectors of the bio/pharma industry heightens, Europe’s implementation of the International Organization for Standardization (ISO) Identification of Medicinal Products (IDMP) continues to progress apace under the European Medicines Agency’s (EMA’s) substance, product, organization, and referential (SPOR) programme (1). To learn more about the ISO IDMP and the way that data and documents will need to be addressed in the future for bio/pharma companies, BioPharm International spoke with James Kelleher, CEO of Generis; and Frits Stulp, managing director, and Remco Munnik, associate director, both of Iperion Life Sciences, a Deloitte company.

Read this article in BioPharm International’s March 2022 Regulatory Sourcebook eBook.

About the author

Felicity Thomas is the European editor for BioPharm International.

Article details

BioPharm International
eBook: Regulatory Sourcebook
March 2022
Pages: 20–22

Citation

When referring to this article, please cite it as F. Thomas, “The Data Relationship,” BioPharm International's Regulatory Sourcebook eBook (March 2022).